Recently, an NGS cancer panel was approved by Palmetto (a contractor for the Centers for Medicare and Medicaid Services) for patients with advanced non-small cell lung cancer, however, patients must have previously tested negative for EGFR mutations, ALK rearrangements and ROS1 rearrangements through non-NGS methods (MolDX: NSCLC, Comprehensive Genome Profile Testing (L35896)). This evidence concerns the gene EGFR and cancer.